# Ferring Pharmaceuticals

Source: https://onco.cc/companies/ferring/  
OnCo record `ferring` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ferring is the private Swiss pharma that brought the first bladder cancer gene therapy, Adstiladrin, to market.

## Summary

Ferring Pharmaceuticals, a private Swiss company based in Saint-Prex, brought the first bladder cancer gene therapy, Adstiladrin, or nadofaragene firadenovec, to market. Nadofaragene was approved in 2022 and launched in 2023 to 2024 after manufacturing scale-up, and the company also makes degarelix for prostate cancer alongside its reproductive medicine and gastroenterology franchises. OnCo links it to bladder and urothelial cancer and to the nadofaragene and degarelix drug records. Whether a gene therapy given into the bladder can hold its position as oncolytic virus and IL-15 competitors arrive is the open question. Nadofaragene firadenovec has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-07
- HQ: Saint-Prex
- Type: pharma
- Website: https://www.ferring.com

## Sources

- Official website: https://www.ferring.com

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Degarelix](https://onco.cc/drugs/degarelix/), [Nadofaragene firadenovec](https://onco.cc/drugs/nadofaragene-firadenovec/)
- trials: [A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease](https://onco.cc/trials/nct02663908/), [A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06545955/), [Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients](https://onco.cc/trials/nct00884273/), [Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer](https://onco.cc/trials/nct00833248/), [Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)](https://onco.cc/trials/nct05704244/), [Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06510374/)

---
JSON: https://onco.cc/api/v1/entities/ferring.json